Gadofosveset-enhanced magnetic resonance angiography

Mathias Goyen
University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Abstract: Gadofosveset (Vasovist®, Bayer Schering Pharma AG, Berlin/Germany) is the first intravascular contrast agent approved for use with magnetic resonance angiography in the European Union, Switzerland, Turkey, Canada, and Australia. Gadofosveset reversibly binds to albumin providing extended intravascular enhancement compared with existing extracellular magnetic resonance contrast agents. Prior to approval, gadofosveset underwent extensive testing to evaluate the safety and efficacy of the drug; the clinical trials show that gadofosveset-enhanced magnetic resonance angiography (MRA) is safe and well tolerated in patients with vascular disease and effective for the detection of vascular stenosis and aneurysms. Gadofosveset has the potential to open new horizons in diagnostic MRA by increasing the spatial resolution and the robustness of MRA examinations and facilitating the examination of multiple vascular beds.

Keywords: gadofosveset, Vasovist®, magnetic resonance imaging, magnetic resonance contrast agent, magnetic resonance angiography (MRA)

Introduction

Atherosclerosis is a generalized disease and contributes to cardiac death, stroke, limb loss, and a range of other illnesses. Disease in the major arteries, including the infra-renal abdominal aorta, internal iliac arteries, renal arteries, and peripheral vasculature remains a major cause of morbidity and mortality. For example, the prevalence of disease in the infra-renal abdominal aorta ranges from <3% in patients <60 years old to 20% in patients ≥75 years (Criqui et al 1985; Vogt et al 1992), and the incidence increases with increasing age. As the average age of the population increases, the burden of vascular disease is expected to increase.

Until recently, conventional X-ray angiography (XRA) requiring arterial catheterization and the use of substantial volumes of iodinated contrast agent was the clinical standard practice when a detailed image of the vasculature was required; however, less invasive imaging techniques using X-ray computed tomography (CT) or magnetic resonance imaging (MRI) have been developed. These imaging methods, either without exogenous contrast agents (MRI only) or with exogenous contrast agents (both CT and MRI) have become increasingly popular over the past few years as data have suggested that their accuracy, in some clinical settings, might approach that of the accepted standard diagnostic method, catheter X-ray angiography (XRA) using iodinated contrast agents (Rieker et al 1997; Grist 2000; Tan et al 2002).

MRI is a safe, non-invasive, and widely available imaging technique that has experienced rapid growth over the past decade. Magnetic resonance angiography (MRA), as a more recent development in MRI, uses tailored acquisition sequences to highlight blood flow and is widely used to assist in the management of patients with vascular diseases, especially in the brain. In many vascular beds like peripheral vessels, however, non-contrast MRA is not used routinely in clinical practice due to shortcomings of unenhanced MRA.
What is gadofosveset?
Gadofosveset is the first intravascular contrast agent approved for use with MRA in the European Union, Switzerland, Turkey, Canada, and Australia. Gadofosveset reversibly binds to human serum albumin, providing significantly higher relaxivity and extended intravascular enhancement compared to existing extracellular magnetic resonance contrast agents (Table 1).

MS-325 is the product development code for the drug product containing trisodium-((2- (R)-(4,4-diphenylcyclohexyl)phosphonoxyethyl)-diethylenetriaminepentaaetate) (aqo) gadolinium(III) (INN (international non-proprietary name) = gadofosveset trisodium) as the active substance. Gadofosveset is commercially available as Vasovist® (Bayer Schering Pharma AG, Berlin/Germany). Gadofosveset injection is composed of an aqueous solution (244 mg/mL, 0.25 mmol/L) of drug substance, gadofosveset trisodium, and a small amount of ligand excipient, fosveset, to ensure minimal free gadolinium in solution. The drug substance consists of a stable gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) chelate substituted with a diphenylcyclohexyl-phosphate group. Gadofosveset injection is a clear, colorless to slightly yellow solution in which the pH has been adjusted to 6.5 to 8.0. The density is 1.12 g/mL and the osmolality ranges from 700 to 950 mOsm/kg at 37 °C. The viscosity of MS-325 injection ranges from 2.7 to 3.3 cps at 20 °C. The molecular formula is C_{33}H_{40}GdN_{3}Na_{3}O_{15}P and the molecular weight for the anhydrous form is 975.88. Gadofosveset is administered either by a hand or power injector to deliver a dose of 0.03 mmol/kg (in 7–20 seconds).

Overview of the clinical development program
Prior to approval in the European Union, gadofosveset underwent extensive evaluation of the safety and efficacy of the drug. The clinical development program for efficacy included two phase II studies and four phase III studies. In phase II studies, approximately 300 patients were evaluated to define optimal dose for MRA. The optimal dose for MRA was found to be 0.03 mmol/kg.

The clinical effectiveness of gadofosveset was demonstrated through analysis of efficacy data of 672 patients that were included in four adequate and well-controlled phase III studies. Vascular beds representative of areas of turbulent blood flow (AIOD: aorto-iliac occlusive disease), flow to an organ (renal artery disease), and slow flow (pedal arterial disease) were studied. In all of these studies, the fundamental methodology was the same:

- Each study was designed to evaluate and quantify the improvement provided by the administration of gadofosveset compared with the MRA device alone (TOF-MRA) using XRA as the standard of reference (SOR);
- All images were acquired using prospectively defined imaging protocols;
- The efficacy evaluation of all studies included blinded reading and 3 independent blinded readers for each study were used. These blinded readers had no prior affiliation with the sponsor, and had not participated in other gadofosveset studies;
- A total of 32 independent blinded readers (24 radiologists, 8 vascular surgeons) were used in the four studies. Vascular surgeons were asked to evaluate the images for management decisions;
- Images were randomized and no other clinical information was provided to the blinded readers;
- Three different blinded readers evaluated XRA images to develop the SOR (2 readers plus 1 adjudicator). No consensus reading was performed in determining the SOR.

Summary of efficacy results of four phase III studies
Gadofosveset reduced the rate of uninterpretability significantly and improved the diagnostic confidence (Goyen et al 2005; Rapp et al 2005). Fewer than 2.3% were uninterpretable for gadofosveset-enhanced MRA, versus approximately 16% for 2D-TOF. For comparison, 2.8% of the vessels were deemed uninterpretable on XRA. For all readers in all studies, the vascular surgeon readers agreed with XRA more often when using gadofosveset-enhanced MRA than when using pre-contrast MRA (range of improvements: 1%–36%). For six of the eight readers, the improvement was substantial (>15%) and statistically significant (p < 0.001).

Safety data for gadofosveset
Safety data in 767 patients (505 males and 262 females) receiving 0.03 mmol/kg bw dose have been reported. There were no clinically significant trends found in adverse events, laboratory assays, vital signs, ECGs, or oxygen saturation.
Gadofosveset has a good safety profile and can be safely administered as an intravenous bolus injection. The overall rate and experience of adverse events was comparable to placebo and were similar to that reported in clinical trials for other Gd chelates.

**Clinical applications of gadofosveset-enhanced MRA**

Considering the enormous success of extracellular gadolinium-based contrast agents for contrast-enhanced MRA, what is likely to be the role for an intravascular contrast agent such as gadofosveset? The answer lies in the key question: can gadofosveset be used in first-pass (arterial) imaging with equal effect? As the answer appears to be yes, this suggests that gadofosveset can be used instead of the current extracellular contrast agents for first-pass arterial imaging (Klessen et al 2007) (Figures 1–4). The crucial advantage of gadofosveset, ie, the presence of persistent high intravascular enhancement significantly greater than with extracellular agents, can be exploited to acquire additional high-resolution images in
the steady-state which lead to a better delineation of vessel pathology. Steady-state imaging offers the possibility of depicting the entire vascular system without relevant extravasation of the contrast medium from the intravascular space. The extended diagnostic window of gadofosveset makes the examination more convenient because it is less dependent on the bolus dynamics.

**General considerations**

Gadofosveset can be used in exactly the same way as extracellular agents with regard to first-pass imaging. The advantage of using gadofosveset for first-pass imaging lies in its much higher relaxivity (Rohrer et al 2005). This means that a higher signal-to-noise ratio can be obtained when parameters are kept identical or, conversely, that spatial resolution can be increased while maintaining the same signal-to-noise ratio. The truly interesting property of gadofosveset, however, is its much longer intravascular residence time. Equilibrium imaging is possible because, despite the fact that dilution of the injected contrast medium after first arterial passage leads to a T1 increase of the blood pool compared with the first pass, the value is still much lower than that of fat. Hartmann et al (2006) estimated that T1 of blood in the equilibrium phase, 3–5 minutes after injection of 0.03 mmol/kg gadofosveset, is about 130 ms, increasing to about 150 ms after 10–15 minutes. This prolonged T1 reduction offers the opportunity to obtain images of the vascular tree up to about 45–60 minutes after injection. The extended imaging window can be used to acquire images with much higher spatial resolution without a significant loss of vessel-to-background contrast (Figure 1). In clinical practice this means that scan duration is no longer determined by the transient T1 shortening, but by the capacity of the patient to sustain a breath-hold or to remain motionless. A possible drawback of using gadofosveset is the simultaneous enhancement of venous structures close to arteries. This phenomenon is a well-known problem
at first-pass imaging, often resulting in images that cannot be used for clinical decision-making. However, because equilibrium phase images can be acquired at much higher spatial resolution – often with a 5–15-fold decrease in voxel size compared with first-pass protocols – arteries can be readily separated from accompanying veins.

**Practical aspects**

The use of gadofosveset has reduced the deleterious consequences of missing the bolus in the first pass. If, for whatever reason, acquisition in the first pass fails, images can always be obtained in the equilibrium phase because of the prolonged intravascular retention. Although prolonged intravascular retention is highly advantageous, it is not recommended to perform a test bolus when using gadofosveset because of this property. If possible, it is better to acquire a dynamic series of acquisitions using a time-resolved MRA technique and to evaluate the data set with the best selective arterial opacification. The most commonly used format to display 3-D MRA data is the maximum intensity projection (MIP). Although MIP is an elegant way to collapse a 3-D volumetric data set into a 2-D projection, review of cross-sectional images remains an integral part of the evaluation, especially for data acquired in the equilibrium phase. The MIP algorithm works
best when using thin-slab or curved subvolume selections. In whole-volume MIPs, contrast-enhancing organs or other vascular structures may superimpose over smaller arteries when they have higher signal intensities along a particular viewing path. When working with equilibrium-phase images, the use of thin-slab sub-volume MIPs can be particularly useful. Another helpful technique for the precise evaluation of vessel morphology, especially when evaluating equilibrium phase data, is curved multiplanar reformation (cMPR) along the axis of the arterial segment of interest. Most post-processing workstations offer the ability to interactively generate a cMPR while scrolling through source images. This technique is particularly useful to obtain views of eccentric stenoses, and as a basis to generate views perpendicular to the central axis of the vessel to measure cross-sectional area reduction in stenoses.

**Gadofosveset-enhanced MRA of the abdomen**

For the diagnostic assessment of the abdominal vasculature, contrast-enhanced (CE)-MRA – together with computed tomography angiography (CTA) – has become the clinically accepted standard of reference and has replaced conventional digital subtraction angiography. In abdominal aortic aneurysm or dissection, CE-MRA allows a simultaneous assessment of the aneurysmal extent and involvement of the renal, visceral or iliac arteries. With gadofosveset, the first pass of the compound can be used for time-resolved MRA, allowing a dynamic assessment of the perfusion of the visceral organs and visualization of blood-flow differences in the true and false lumen of aortic dissection (Schoenberg et al 1999). In patients with endovascular repair of abdominal aortic aneurysm, blood-pool agent-enhanced MRA might be more accurate for the detection of endoleakage than contrast-enhanced CT (Ersoy et al 2004). In patients with atherosclerotic disease, the potential to increase the spatial resolution during the steady state promises a higher accuracy for the detection of vascular stenoses than conventional MRA with extracellular contrast agents. In patients with aortoiliac disease, Vogt et al (2007) reported a higher agreement regarding stenosis location and degree of stenosis of gadofosveset-enhanced MRA and DSA compared with a non-contrast, time-of-flight MRA.

In a study by Nikolaou et al (2006), gadofosveset-enhanced MRA showed a sensitivity of 97%–100% and specificity of 96%–100% for the assessment of high-grade stenosis in different vascular territories (eg, carotid or renal arteries) compared with the clinical standard of reference. In this study the intermodality agreement between the gadofosveset-enhanced imaging and reference CE-standard imaging data was 90%–93%.

CE-MRA is the clinical gold standard for the detection of renal artery stenosis (RAS). Due to the limited breath-hold capacity of the patients, imaging has to take place during suspended breath-hold, limiting acquisition time and thereby reducing the spatial resolution. While proximal RAS can still be safely detected, fibromuscular dysplasia (FMD) may potentially evade detection. Gadofosveset as a blood pool contrast agent may overcome this limitation of MRA by facilitating longer respiratory-gated MRA acquisitions. Due to the widespread use of 3-D post-processing tools, the venous signal does not interfere with diagnostic image reading. In addition, the first pass of the contrast agent can be used to measure renal perfusion (Michaely et al 2006). Due to the high relaxivity
of gadofosveset, only a fraction of the amount of gadolinium that would be required for extracellular contrast agents is needed. This is of particular interest in view of the recently described disease ‘nephrogenic systemic fibrosis’, which is more likely to occur when higher doses of gadolinium are administered (Leiner et al 2007). Gadofosveset may also be valuable in patients who are being evaluated as potential renal donors, as the entire abdomino-pelvic arterial and venous system can be examined after a single injection of contrast agent. This eases workflow and should eventually be more cost-efficient.

Gadofosveset-enhanced MRA of the thorax

The assessment of the pulmonary arteries for pulmonary embolism is an interesting application for gadofosveset-enhanced MRA. Although CT is nowadays the first-line imaging tool for the assessment of patients with suspected pulmonary embolism, contrast-enhanced MRI is very appealing as it allows for a comprehensive radiation-free assessment of pulmonary perfusion and direct visualization of embolic material in the pulmonary arteries using a single contrast agent injection. Moreover, MR venography of the deep venous system can be added for the assessment of underlying deep venous thrombosis without an additional contrast agent (Fink et al 2004). Recently, an animal study indicated that the higher relaxivity of a blood pool contrast agent together with the increased signal-to-noise ratio of 3 T effectively supports highly accelerated, parallel acquisition, time-resolved pulmonary MRA (Nael et al 2007).

For cardiac imaging, the direct visualization of coronary arteries is a major challenge for MRI. Although multislice-CT coronary angiography is now the preferred non-invasive imaging technique for the assessment of coronary disease, blood-pool contrast agents may change the role of CE-MRA. Animal and volunteer studies of coronary MRA using blood-pool agents have been reported by different authors using different blood-pool contrast agents. Though heterogeneous in their set-up, all studies reported a significant advantage.

Figure 4 Patient with symptomatic abdominal aortic aneurysm referred for peripheral MRA. The high grade stenosis of the left internal carotid artery was confirmed by 64 multi-slice CTA and the patient was discharged after successful thrombendarterectomy and aneurysm repair. After first-pass MRA of the abdomen and lower extremities (A), an ultra-sonographically suspected stenosis of the left internal carotid artery is confirmed by the 0.66 mm isotropic resolution steady-state gadofosveset-enhanced MRA (B, arrow). This approach facilitates the pre-operative work-up of patients with systemic vascular disease without the need of a second contrast injection or a separate MR-examination. Image courtesy Winfried Willinek, Department of Radiology, University of Bonn/Germany.

**Gadofosveset-enhanced MRA of the peripheral vasculature/whole-body MRA**

CE-MRA of the peripheral vasculature has evolved over the past few years from an experimental imaging modality to a technique that is now widely applied in clinical practice. The recent introduction of gadofosveset expands the diagnostic armamentarium of the radiologist by opening up new opportunities in the field of peripheral MRA. The higher relaxivity and prolonged intravascular residence time of gadofosveset yield better first-pass image quality, as well as the possibility of obtaining additional steady-state MRA data. The latter property will lead to a fundamental paradigm shift in MR imaging of the vasculature, enabling the migration to equilibrium-phase ultra-high spatial resolution imaging sequences. Initially, there were concerns in regard to the presence of venous overlay on the steady-state 3D-CE-MRA data sets, particularly for arteries with small vessel calibre and close-by coursing veins such as in the distal calves. However, with today’s optimized surface coils and the use of PAT, isotropic voxel sizes of less than 100 µm³ can now be acquired in reasonable scan time of approximately 5 min (Nikolaou et al 2006) (Figure 1, Figure 3). Due to the absence of motion artefacts in the peripheral arteries, exquisite image quality can be achieved allowing already for visual artery-vein separation despite the close proximity of these vessels. Artery-vein separation can be further enhanced by the use of semi-automated software, which is currently under preparation by different vendors. Gadofosveset-enhanced MR imaging of the venous system is ideally suited to the detection of venous thromboembolic disease. Deep venous thrombi, even below the knee, are readily detected (Li et al 2007). Furthermore, in patients with massive thromboembolic occlusion of central veins, the collateral pathways can reliably be visualized in a fashion that is superior to conventional X-ray-based venography.

With the introduction of whole-body MRI scanners with multiple independent rf-channels and inbuilt coil systems for large anatomic coverage this approach becomes attractive for assessment of the entire vasculature by a combination of multi-station first-pass 3D-CE-MRA and steady-state 3D-CE-MRA. This shifts the focus of MRA away from solely displaying vascular anatomy to a more disease specific imaging approach. One example includes the systemic assessment of atherosclerotic disease, which has been shown as an arising application for screening of cardiovascular risk factors in preliminary studies (Kramer et al 2005) (Figures 2–4). This systemic angiographic assessment is also of high interest for patients with vasculitis such as Takayasu arteritis that manifests in multiple different locations. Here, the combination of first-pass 3D-CE-MRA of the carotid and renal arteries in combination with high-resolution assessment of the inflammatory stenoses could improve the overall diagnostic work-up of the patients and replace a more time-intensive, multi-step, multi-modality approach.

**Conclusion**

Gadofosveset-enhanced MRA is safe and well tolerated in patients with vascular disease, effective for the detection of vascular stenosis and aneurysms, significantly more accurate (both more sensitive and specific) than non-contrast MRA for the diagnosis of vascular stenoses, and similar to conventional angiography for the overall characterization of vascular disease, without the need for catheterization. Gadofosveset has the potential to open new horizons in diagnostic MRA by increasing the spatial resolution and the robustness of MRA examinations and facilitating the examination of multiple vascular beds.

**References**


